Xaira Therapeutics develops predictive and agentic artificial intelligence models across the drug discovery and development spectrum. This AI approach aims to enhance predictions regarding target biology, therapeutic modulation, and patient benefit for specific diseases. The company seeks to engineer therapies to increase success probability, shorten development timelines, and reduce overall costs in medicine creation.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery and development processes are often inefficient, costly, and time-consuming, hindering the rapid creation of effective therapies. These inefficiencies stem from a lack of data-driven insights and predictive models to guide research and development efforts.
Solution
Xaira Therapeutics is developing an integrated biotechnology platform that leverages artificial intelligence (AI) and large-scale biological data generation to accelerate drug discovery and development. The company aims to enhance the efficiency of traditional methods by providing data-driven insights and predictive models to its clients. By integrating AI with biological data, Xaira seeks to optimize the drug development pipeline, leading to the faster creation of transformative medicines.
Target Audience
Xaira's primary customers are pharmaceutical companies and research institutions seeking to improve the efficiency and effectiveness of their drug discovery and development processes.
Features
- Integrated biotechnology platform combining AI and biological data generation
- Data-driven insights to guide drug discovery
- Predictive models to accelerate drug development